Kronox Lab Sciences Limited

As of June 30, 2026, Kronox Lab Sciences Limited carries a market capitalization of 5.56B, placing it among publicly traded companies globally. Its enterprise value stands at 5.56B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, Kronox Lab Sciences Limited has 37.10M shares outstanding.

As of June 30, 2026, Kronox Lab Sciences Limited trades at a trailing price-to-earnings ratio of 19.30.

As of June 30, 2026, Kronox Lab Sciences Limited trades at an EV/EBITDA multiple of 15.81 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 5.28 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 16.82 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 5.56B versus a market cap of 5.56B, with the gap driven by net debt and cash on the balance sheet.

These figures are as of June 30, 2026.

Over the twelve months ended June 30, 2026, Kronox Lab Sciences Limited recorded 99.88M in income tax expense. That works out to an effective tax rate of 25.90, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 385.59M, leaving 285.70M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 23, 2026, Kronox Lab Sciences Limited's stock has gained approximately 25.11% over the past 52 weeks. The 50-day moving average sits at 188.75, while the 200-day moving average is 147.79.

Over the twelve months ended June 30, 2026, Kronox Lab Sciences Limited generated 1.05B in revenue and converted that into 285.70M in net income, yielding earnings per share of 7.77. EBITDA reached 351.87M, while operating income came in at 330.88M.

Over the twelve months ended June 30, 2026, Kronox Lab Sciences Limited posted a gross margin of 53.56, reflecting its pricing power and cost economics. The operating margin of 31.42 and net profit margin of 27.13 provide insight into operational efficiency.